The Model That Changed Biotech

Twenty years ago, a credible pharmaceutical development programme needed laboratories, equipment, and scientists on the payroll. The idea that a five-person team could advance a drug candidate from lead optimisation to Phase II without owning a single centrifuge would have seemed implausible.

Today it is routine. The virtual biotech model, built on outsourcing relationships with CDMOs, CROs, and specialist consultants, has become one of the dominant organisational forms in early-stage pharmaceutical development. It allows small teams to access world-class scientific and manufacturing capabilities without the capital overhead, and it lets investors fund science rather than infrastructure.

It also fails regularly, for predictable reasons that have nothing to do with the science.

What Goes Wrong in Virtual Biotech Programmes

Too Many Vendors, Not Enough Oversight

The instinct of many virtual biotech teams is to find the best vendor for each individual piece of work. Best formulation house for development, best CRO for animal studies, best CMO for manufacturing. The result is a programme spread across five or six organisations with no single point of accountability and a coordination overhead that consumes the management team.

No Internal CMC Expertise

A virtual biotech can outsource the execution of CMC work. It cannot outsource the judgement about what CMC work is needed. Without someone on the team who understands what a regulator will expect to see in Module 3, the programme can spend months generating data that does not answer the right questions.

The Tech Transfer That Should Not Have Existed

Many virtual biotechs develop a molecule with one vendor, then transfer it to a different GMP manufacturing partner because the first vendor does not have GMP capability. Every tech transfer is a risk event. Data is interpreted by new people, processes are reproduced on different equipment, and unexpected results emerge. The transfer that could have been avoided by choosing an integrated partner from the start costs months and money to resolve.

What Successful Virtual Biotechs Do Differently

Success Factor	What It Looks Like in Practice
Choose an integrated partner early	Select a CDMO with development and GMP manufacturing capability at the start; avoid planned tech transfers between development and manufacturing
Keep CMC expertise internal	Hire or retain a Head of CMC or CMC consultant with regulatory filing experience; do not rely on the CDMO to own regulatory strategy
Define deliverables, not activities	Contract for outcomes (Phase I CMC package) rather than activities (12 months of stability work); gives the CDMO flexibility to design the most efficient programme
Build in formal decision gates	Schedule quarterly scientific reviews where the programme strategy is assessed against the data, not just the timeline
Use project management tools the CDMO actually supports	Do not assume the CDMO will use your project management system; agree on reporting format and frequency before work starts
Plan for the unexpected	Build contingency time and budget into the plan; virtual programmes with no slack are brittle when something goes wrong

The Integrated CDMO as a Virtual Biotech’s Scientific Department

For a five-person virtual biotech, the CDMO is not just a service provider. It is, functionally, the scientific organisation. The quality of the science that goes into the programme, the data generated, the decisions made, the regulatory strategy pursued, is largely determined by the quality and engagement of the CDMO team.

This is why the consultative tone that characterises good CDMO partnerships matters more for virtual biotechs than for large pharma. A CDMO that executes instructions without pushing back when the science suggests a different approach is not providing the partnership a virtual biotech needs. A CDMO that raises the question about polymorph stability before the first GMP batch is planned, that flags the dissolution method issue before the IND is filed, is providing something genuinely valuable.

How Ardena Supports Virtual Biotech Programmes

Ardena’s model is particularly well suited to virtual biotech programmes. The integrated multi-site network covers solid state research, formulation development, analytical services, GMP manufacturing, bioanalysis, and regulatory support under a single project management framework. For a virtual biotech that does not have scientific departments of its own, Ardena provides the depth of capability that would otherwise require five separate vendor relationships.

The Document Nobody Reads Until Something Goes Wrong

Quality agreements are one of those documents that get negotiated carefully, signed by the right people, filed away, and never looked at again. Until something goes wrong.

When a GMP deviation occurs, when a batch fails, when a regulatory inspection raises a question about oversight, the quality agreement is the document that defines who was responsible for what. If it is vague, incomplete, or has not been reviewed since the programme started, the consequences are predictable.

A good quality agreement is not just a legal formality. It is a genuine operational tool that prevents disputes, clarifies accountability, and ensures that GMP responsibilities are distributed logically between the sponsor and the CDMO.

The Regulatory Requirement

EU GMP Chapter 7 on outsourced activities and the FDA’s guidance on contract manufacturing both require written quality agreements between sponsors and their contract manufacturers. The agreement must define the GMP responsibilities of each party clearly and must be reviewed and approved by the quality units of both organisations. It is not sufficient for a general commercial contract to contain quality provisions; a standalone technical or quality agreement is the regulatory expectation.

What a Strong Quality Agreement Covers

Section	What It Should Define	Common Weakness
Scope of work	Exactly which activities are covered; what is in scope and out of scope for the agreement	Scope defined too broadly; changes in the programme not captured by agreement updates
GMP responsibilities	Which party is responsible for each GMP activity: batch record review, release, deviation investigation, CAPA	Joint responsibilities listed without specifying the primary responsible party
Change control	Which changes require sponsor notification; which require sponsor approval before implementation	CDMO retains right to make process changes without sponsor approval; sponsor not notified in time
Deviations and OOS	Timelines for notification; who investigates; who approves the investigation report	Notification timelines too loose; sponsor does not receive deviation reports until batch review
Regulatory inspections	What each party does when the other is inspected; how the agreement is referenced in submissions	No provision for inspection support; sponsor not informed of CDMO inspection findings
Stability	Who owns the stability programme; who has responsibility for out-of-trend results	Stability ownership split between parties without clear escalation path
Batch release	Authorised person responsibilities; what happens when the sponsor and CDMO disagree on release	Release responsibility assumed but not explicitly assigned; AP not named
Annual product review	Which party leads the APR; what data the CDMO provides; timelines	APR responsibility not assigned; CDMO data not available when sponsor needs it

The Change Control Problem

Change control is the section of quality agreements that generates the most disputes in practice. The question is simple: when the CDMO wants to change something about the manufacturing process, the equipment, the supplier, or the facility, what does it need to tell the sponsor, and when?

From the CDMO’s perspective, the ability to make routine operational improvements without seeking sponsor approval for every change is a reasonable operational requirement. From the sponsor’s perspective, any change to the process that manufactured their clinical batches is a potential CMC filing issue that could trigger a regulatory amendment.

The resolution is a tiered change control classification. Minor changes are notified; significant changes require sponsor review; major changes require sponsor approval before implementation. What counts as minor, significant, or major should be defined explicitly in the agreement, not left to interpretation.

Reviewing and Updating the Agreement

Quality agreements should be reviewed at least annually and updated whenever the scope of work changes materially. A quality agreement written at the start of a Phase I programme will not adequately cover the same programme at Phase III. New manufacturing sites, new dosage forms, and new regulatory filings all need to be reflected in the document.

In practice, quality agreements often lag behind the programme. Amendments are negotiated slowly, and in the meantime the teams operate under informal understandings that have no contractual force. Building a formal review cycle into the programme management plan, with responsibility assigned to a named individual on each side, is the most reliable way to prevent this.

How Ardena Approaches Quality Agreements

Ardena’s quality team produces quality agreements that are specific to each programme rather than generic templates with blanks filled in. The change control classifications, notification timelines, and responsibility assignments in an Ardena quality agreement reflect the actual work being done and the regulatory context of the programme.

Why a US Site Matters

For biotech companies based in North America, time zone alignment and proximity are not trivial. A development partner eight hours ahead means decisions made in the afternoon do not get actioned until the next day. Equipment access, sample shipping, and site visits all become harder when the facility is on another continent.

Ardena’s Somerset, New Jersey site gives North American sponsors a US-based manufacturing partner with direct access to the oral solid and bioavailability enhancement capabilities the Ardena network is known for. The same scientific standards, the same quality systems, the same integrated project management, but in the same time zone.

What the Site Does

Spray Drying for Amorphous Solid Dispersions

Somerset’s core strength is spray-dried amorphous solid dispersion (ASD) manufacture. The site operates laboratory and GMP-scale spray drying equipment with closed-loop solvent recovery and secondary drying capability. The formulation team has developed ASDs across a wide range of BCS Class II molecules and polymer systems, including HPMC-AS, PVPVA, and PVP-K grades.

Development programmes at Somerset start with feasibility: does this molecule respond to ASD? If yes, which polymer gives the best balance of dissolution performance, physical stability, and processability? From there, the team scales through development batches to GMP clinical manufacture within the same facility, with no formal tech transfer between scales.

Hot Melt Extrusion

HME capability at Somerset serves molecules where spray drying is less suitable, typically thermally stable APIs where a solvent-free process is preferred or where the downstream processing of a spray-dried powder presents challenges. The site’s HME expertise covers twin-screw extrusion, extrudate milling, and downstream tabletting or capsule filling of the milled intermediate.

Downstream Oral Solid Manufacturing

Somerset handles the full downstream processing chain for ASD-based products: granulation where required, blending, tabletting, and capsule filling. Analytical capabilities support content uniformity, dissolution testing, and stability studies from development through to GMP release.

Who Somerset Is Built For

Programme Type	Why Somerset Is a Good Fit
BCS Class II molecules needing ASD strategy	Spray drying and HME under one roof; formulation screening to GMP clinical batch at a single site
North American sponsors wanting US-based manufacturing	Same time zone; direct site access; FDA cGMP operations; no import/export logistics for US clinical supply
Programmes requiring dual US/EU clinical supply	Somerset provides FDA cGMP US supply; Ghent or Pamplona provides EU GMP supply under coordinated Ardena project management
Early-phase ASD feasibility with tight timelines	Rapid screening capability; formulation team responds quickly; no transatlantic coordination overhead
IND-stage oral solid programmes	Experience preparing CMC sections for IND submissions; regulatory team aligned with FDA expectations

The Connection to the European Network

Somerset is not an isolated US operation. It is a node in the Ardena network, with direct scientific and project management connections to Ghent, Oss, Assen, and Pamplona. For programmes where solid state work needs to happen in Ghent before formulation development begins in Somerset, the handoff is internal. For programmes requiring EU GMP supply for European trials alongside US supply from Somerset, a single project manager coordinates both.

That integration removes the coordination overhead that sponsors would otherwise manage themselves when using a US development house alongside a separate European manufacturer.

The Site Built for Difficult Molecules

Not every pharmaceutical development programme involves a straightforward API in a standard formulation. Some molecules are highly cytotoxic. Some are scheduled narcotics. Some are biologically active at doses measured in micrograms. These are not unusual compounds at the edges of drug development. They are increasingly common in oncology, neurology, and rare disease pipelines.

Ardena’s Pamplona facility, which operates under the Idifarma brand within the Ardena network, is the site in the group best equipped to handle them. OEB 4 and 5 containment, controlled substance manufacturing licences, and a formulation team experienced in the specific challenges of high-potency and low-solubility molecules make Pamplona the natural home for programmes that other sites cannot take on.

HPAPI Manufacturing and Containment

Pamplona’s HPAPI infrastructure includes containment isolators for handling at OEB 4 and 5, dedicated manufacturing suites with independent HVAC systems, and validated decontamination procedures using hydrogen peroxide vapour. The site’s environmental monitoring programme covers HPAPI air monitoring in work areas using validated analytical methods capable of detecting compounds at the nanogram per cubic metre level.

The containment capability supports both drug substance handling (weighing, dispensing, and transfer of HPAPI starting materials and intermediates) and drug product manufacture (blending, granulation, and tabletting of HPAPI oral solid drug products). Yield accountability and mass balance documentation are maintained throughout, meeting the strict record-keeping requirements associated with potent compound manufacturing.

Controlled Substance Manufacturing

Pamplona holds manufacturing authorisations for narcotic and psychotropic substances under Spanish and European regulatory requirements. This enables the site to manufacture clinical batches of scheduled compounds including opioids, cannabinoids, and emerging psychedelic-derived therapeutics within a GMP framework that meets both EU GMP and the specific national requirements of the Spanish competent authority (AEMPS).

The site has experience managing the import and export licence requirements associated with controlled substance clinical supply, and can coordinate with regulatory authorities in importing countries to ensure that cross-border shipments are compliant.

Oral Solid Formulation for Challenging Molecules

Pamplona’s formulation team specialises in molecules that present both potency and solubility challenges simultaneously. The site operates hot melt extrusion and wet milling capability for bioavailability enhancement, alongside standard granulation and tabletting for more conventional formulations. High-sensitivity LC-MS/MS analytical methods are used for content uniformity and dissolution testing of HPAPI drug products where standard HPLC-UV methods lack sufficient sensitivity.

What Pamplona Is Best Suited For

Programme Type	Why Pamplona Is a Good Fit
Oncology HPAPI oral solid	OEB 4-5 containment; formulation development; GMP clinical batch; high-sensitivity analytical methods
ADC payload synthesis or handling	HPAPI containment for cytotoxic warheads; controlled transfer to conjugation chemistry steps
Controlled substance development	AEMPS manufacturing licence; experience with import/export documentation; GMP batch supply for scheduled compounds
Psychedelic-assisted therapy programmes	Schedule 1 and 2 handling capability; experience with regulatory requirements for novel controlled substance clinical programmes
BCS Class II HPAPI formulation	HME and wet milling with containment; simultaneous management of solubility challenge and exposure risk
Low-dose solid dosage forms	Experience with microgram-level content uniformity; validated LC-MS/MS release methods

Integration with the Ardena Network

For ADC programmes, Pamplona’s HPAPI capabilities connect with the formulation and fill-finish work at Ghent and the bioanalytical programme at Assen. For programmes involving solid state uncertainty, Pamplona’s formulation work draws on the solid state research expertise at Ghent. For programmes requiring simultaneous EU and US GMP compliance, Pamplona’s EU GMP certification and the US cGMP status of the Somerset facility together provide the geographic footprint needed for dual submissions.

Where the Clinical Trial Meets the Laboratory

Ardena’s Assen facility sits at the intersection of two things that are normally separated: the bioanalytical laboratory that measures what is happening in patients and the clinical supply operation that gets the drug to them. Bringing these capabilities together under one roof is not just operationally convenient. It means the people designing the patient kit are the same people who will receive the blood samples it generates, and the lessons from one directly improve the other.

Bioanalytical Services at Assen

Small Molecule PK by LC-MS/MS

The analytical chemistry team at Assen provides fully validated LC-MS/MS methods for quantification of small molecule drugs and their metabolites in plasma, serum, urine, and other biological matrices. Studies run under GLP or GCP conditions as required, with ICH M10-compliant validation packages and ISR programmes as standard.

Large Molecule and Immunogenicity Assays

The ligand-binding assay platform at Assen covers PK quantification for biologics including monoclonal antibodies, ADCs, and fusion proteins, alongside the complete tiered immunogenicity testing programme for anti-drug antibody detection and characterisation. MSD electrochemiluminescence and ELISA platforms are both operated, with assay development experience across a wide range of therapeutic targets.

Biomarker and Flow Cytometry

The biomarker team provides fit-for-purpose assay development and validation for pharmacodynamic, safety, and predictive biomarkers using MSD multiplex platforms, single-plex ELISA, and qPCR. The flow cytometry laboratory runs multi-parametric immunophenotyping panels for T cell subset analysis, B cell characterisation, NK cell phenotyping, and MRD assessment in haematological programmes.

Clinical Supply and Patient Kit Services

The clinical supply team at Assen assembles and quality-checks patient kits for clinical trials, including pre-labelled sample collection tubes, visit-specific configurations, cool pack integration, and laminated step-by-step processing instructions designed to minimise site errors. Kits are assembled to programme-specific designs, with barcode labelling, personalisation to patient ID where required, and IATA-compliant packaging for temperature-controlled international shipment.

Sample logistics are managed end to end: kits ship out to investigator sites, samples arrive back at Assen, chain of custody is logged from receipt, and storage conditions are verified against validated stability data before analysis proceeds. The same team that designed the kit handles the incoming samples, which means any recurring collection errors are identified and fed back to sites quickly.

The Scope of What Assen Handles

Service Area	Capability	Regulatory Standard
Small molecule bioanalysis	LC-MS/MS in plasma, serum, urine, CSF, tissue	GLP / GCP; ICH M10 compliant
Large molecule bioanalysis	LBA (MSD, ELISA) for mAbs, ADCs, bispecifics, fusion proteins	GLP / GCP; ICH M10 compliant
Immunogenicity	Tiered ADA screening, confirmation, titration, neutralisation	FDA and EMA guideline compliant
Biomarker assays	MSD multiplex, ELISA, qPCR; fit-for-purpose validation	FFP approach; scope defined by intended use
Flow cytometry	Multi-parametric panels; up to 15+ parameters; immunophenotyping and MRD	Fit-for-purpose; EuroFlow-aligned panel design
Patient kit assembly	Visit-specific kits, barcode labelling, cool pack integration, IATA packaging	Quality-controlled assembly; batch records
Clinical sample logistics	Receipt, chain of custody, condition verification, storage management	GCP-compliant sample handling
Global clinical distribution	IMP storage and distribution to EU and international sites; customs coordination	GDP-compliant distribution; temperature-monitored

Connecting Assen to the Rest of the Ardena Network

Bioanalytical data from Assen is interpreted alongside PK, PD, and safety data generated across the wider clinical programme. For nanomedicine programmes, the nanoparticle payload bioanalysis at Assen connects directly with the formulation and CQA data from Oss. For ADC programmes, the ADC PK and immunogenicity assays at Assen are coordinated with the HPAPI manufacturing at Pamplona. The integration is structural, not just aspirational.

A Site Built Around Nanoparticles

Ardena’s facility in Oss, the Netherlands, is not a general pharmaceutical site that also does nanomedicines. It is a site designed from the ground up for nanoparticle development and manufacturing. The equipment, the analytical infrastructure, the technical expertise, and the quality systems are all configured around the specific demands of LNPs, polymeric nanoparticles, liposomes, and related complex nanotechnology-based products.

That focus matters. The difference between a general injectable site that can manufacture an LNP and a dedicated nanomedicine site is the same as the difference between a GP and a specialist. The specialist has seen the edge cases, solved the unexpected problems, and built the institutional knowledge that makes the process more reliable.

What Oss Offers

LNP Development and GMP Manufacturing

The formulation team at Oss develops LNP products from initial lipid screening through to GMP clinical batch manufacture. Microfluidics and nanoparticle extrusion platforms are available at development and GMP scale, with integrated tangential flow filtration (TFF) capability for buffer exchange and concentration. The site has experience with mRNA, siRNA, and small molecule LNP products across a range of ionisable lipid systems.

Polymeric and Other Nanoparticle Systems

Beyond LNPs, the Oss team has formulation capabilities for PLGA and other biodegradable polymer nanoparticles, nanosuspensions prepared by wet milling, and lipid-polymer hybrid systems. The common thread is that the site is equipped for the characterisation-intensive development work that nanoparticle products require, with DLS, NTA, RiboGreen encapsulation efficiency assays, and in vitro release testing all available in-house.

Analytical Characterisation

The analytical team at Oss provides the full suite of physicochemical characterisation required for LNP and nanoparticle drug product development, including particle size and PDI by DLS, zeta potential, encapsulation efficiency by RiboGreen or equivalent, lipid composition by HPLC, and mRNA integrity by gel electrophoresis. The team develops the analytical methods needed for GMP batch release and regulatory filing alongside the formulation programme.

The Programmes Oss Is Best Suited to Support

Programme Type	Why Oss Is a Good Fit
mRNA LNP therapeutics	Dedicated microfluidics and TFF equipment; mRNA integrity and potency testing; GMP clinical batch capability
siRNA or ASO LNP	Nucleic acid encapsulation experience; encapsulation efficiency optimisation; GMP manufacturing at clinical scale
Polymeric nanoparticle sustained release	PLGA and polymer nanoparticle development; in vitro release testing; GMP scale-up
Nanosuspension for BCS Class II	Wet milling with particle size characterisation; downstream processing to solid dosage form
LNP regulatory filing support	Integrated regulatory team; experience with Module 3 CMC for LNP products; familiarity with FDA and EMA expectations
Scale-up from development to GMP	Same facility and team at both scales; no formal tech transfer; process parameters maintained consistently

Connection to the Broader Ardena Network

Oss does not work in isolation. For ADC programmes where the payload requires HPAPI containment, the formulation work at Oss connects with the Pamplona facility’s containment manufacturing capability. For bioanalysis of nanoparticle payloads, Oss works alongside the bioanalytical team at Assen. For aseptic fill-finish of finished nanoparticle drug products, Oss programmes can connect to the sterile manufacturing infrastructure at Ghent.

The Site That Does the Most

Of all Ardena’s European sites, Ghent carries the broadest scope. It is where solid state research happens. It is where oral solid development and manufacturing runs. It is also where sterile injectables, lyophilised products, and complex parenteral formulations are developed and manufactured under GMP. For a programme that spans multiple dosage forms or that needs solid state characterisation feeding directly into drug product development, Ghent is where those conversations happen in one building.

Solid State Research

The solid state research group in Ghent is dedicated to pre-formulation work: polymorph screening, salt and co-crystal screening, hydrate and solvate assessment, and the characterisation of physical and chemical properties that determine how a molecule will behave in a formulation. The team works with XRPD, DSC, TGA, DVS, and Raman spectroscopy as its core analytical toolkit.

What makes the Ghent setup particularly effective is the direct connection between solid state research and drug product development. The scientist who identifies the optimal salt form is part of the same organisation as the scientist who will formulate the tablet. Decisions made in pre-formulation are informed by what the downstream process can accommodate, rather than handed over in a report and interpreted by someone else months later.

Oral Solid Development and Manufacturing

Ghent’s oral solid development team covers the full formulation development pathway for tablets and capsules: pre-formulation, formulation screening, process development, and scale-up to GMP clinical batch manufacture. The site operates batch and continuous manufacturing capability for tabletting, granulation (wet and dry), film coating, and capsule filling.

PAT tools including near-infrared spectroscopy are integrated into the manufacturing environment, supporting blend uniformity monitoring and granulation endpoint determination. The team has experience with immediate release, modified release, and enteric-coated dosage forms, and with challenging APIs including poorly soluble compounds that require bioavailability enhancement strategies.

Sterile Manufacturing and Lyophilisation

The sterile manufacturing suite at Ghent provides aseptic fill-finish for vials and ampoules under Grade A conditions within a RABS environment. Lyophilisation capacity supports both conventional small molecule injectables and biologics requiring freeze-drying for stability.

The sterile manufacturing team has experience with complex injectable formulations including liposomal products and nanoparticle drug products requiring the specific process controls and in-process monitoring discussed in the broader nanomedicine fill-finish programme. Environmental monitoring and media fill qualification are maintained to EU GMP Annex 1 standards.

Analytical and Regulatory Support

Ghent’s analytical teams provide method development and validation for both oral solid and injectable products. The regulatory team in Ghent contributes to CMC dossier preparation for IND and IMPD submissions, with particular expertise in the solid state and oral solid sections of Module 3.

What Ghent Is Particularly Well Suited For

Programme Type	Why Ghent Is a Good Fit
Early-phase oral solid with solid state uncertainty	Solid state research and formulation development in the same site; findings translate directly into formulation decisions
Poorly soluble oral API	HME, wet milling, and lipid formulation capabilities alongside solid state analytics
Sterile injectable for Phase I	Aseptic fill-finish under EU GMP; lyophilisation available; experienced with small clinical batches
Liposomal or nanoparticle injectable	Specialist experience in nanoparticle fill-finish process development; particle size monitoring during filling
Programme needing dual IMPD/IND filing	EU GMP certified site; regulatory team experienced in both jurisdictions
Continuous manufacturing evaluation	Batch and continuous manufacturing capability; PAT tools in place; team experienced in Q13 requirements

Working with the Ghent Team

Projects based primarily at Ghent are managed by dedicated project managers who coordinate work across the solid state, formulation, analytical, and manufacturing teams within the site. For multi-site programmes, the Ghent project manager integrates with counterparts at Oss, Assen, Pamplona, and Somerset to ensure that the work is coordinated and that data flows between teams without friction.

Why the Geography of Your CDMO Partner Matters

The choice to develop a drug in Europe rather than the United States is not just a matter of geography. It affects your regulatory strategy, your manufacturing standards, the reference points in your CMC dossier, and ultimately the timeline to your first clinical data. For many biotech companies, particularly those seeking approval in both markets, understanding the interplay between EMA and FDA requirements from the outset saves significant rework later.

Key Regulatory Differences: EMA vs. FDA

Regulatory Element	EMA (European)	FDA (United States)
Pre-clinical to Phase I submission	IMPD (Investigational Medicinal Product Dossier) in CTD format	IND (Investigational New Drug application)
GMP standard	EU GMP (EudraLex Vol 4)	cGMP (21 CFR Parts 210/211)
Regulatory inspection framework	National Competent Authorities + EMA	FDA CDER/CBER inspection
CMC data expectations at Phase I	Pragmatic; fit-for-purpose with defined limitations	Similar; FDA responsive to first-cycle CMC deficiency letters
Paediatric obligation	Paediatric Investigation Plan (PIP) required	Paediatric Study Plan (PSP) under PREA
Advanced therapy products	ATMP Regulation (1394/2007), CAT committee	BLA/NDA process through CBER
Clinical trial authorisation	Single CTA per Member State or EU CTA (CTIS)	IND filing covers US clinical sites

The Advantages of Developing in Europe

EU GMP Is Recognised Globally

EU GMP certification is accepted by a wide range of health authorities beyond Europe, including those of Australia, Canada, Japan, and many emerging markets. Developing under EU GMP from the outset means your manufacturing data is audit-ready for more markets without additional inspection overhead. The EU GMP mutual recognition agreements with the FDA and other agencies further reduce duplication for globally-focused programmes.

Parallel IMPD/IND Submissions Are Achievable

For companies targeting both EU and US clinical trials, a well-structured CMC dossier developed in Europe can form the basis of both an IMPD and an IND submission. The CTD format (Common Technical Document) was designed precisely to enable this, with Module 3 quality data common to both applications. A CDMO with experience in dual submissions can build that efficiency into the development plan from the start.

Cost-Effective Early Development

For pre-clinical and Phase I work, European CDMOs often offer highly competitive pricing relative to comparable US facilities, with equivalent or superior scientific capabilities. For a capital-efficient biotech, that cost advantage at the development stage can meaningfully extend the runway to the next funding milestone.

How Ardena Supports Multi-Jurisdictional Programmes

Ardena’s facilities are authorised under EU GMP and operate within regulatory environments that are routinely inspected by national competent authorities across Belgium, the Netherlands, Spain, and the US FDA. The organisation has experience preparing CMC sections for both IMPD and IND submissions, and can advise on where regulatory strategies diverge between jurisdictions.

For programmes seeking to run EU and US trials in parallel, Ardena’s regulatory team can help structure the CMC development plan to produce data that satisfies both agencies without duplicating the experimental work

Where Outsourced Programmes Actually Go Wrong

In a post-mortem analysis of delayed pharmaceutical development programmes, the root cause is rarely technical. It is almost always communication. The formulation team changed the API particle size specification but did not formally notify the manufacturing team. The client expected a stability report in a format that the CDMO was not using. A critical experiment was delayed because no one flagged the resource conflict two weeks in advance.

None of these are scientific failures. They are project management failures, and they are extraordinarily common in pharma outsourcing relationships.

What Good Project Management Looks Like in CDMO Partnerships

A Single Named Point of Contact

The most important feature of a well-managed CDMO partnership is having one person who owns the programme. Not a team. Not a department. One named project manager who attends every meeting, tracks every deliverable, and is accountable to the client for the health of the programme. When issues arise, you know exactly who to call, and that person knows exactly what is happening across every workstream.

Structured Reporting Cadence

Regular progress reports, written to a consistent template, give clients a clear view of what has been completed, what is in progress, and what is at risk. The best CDMOs produce reports that are informative regardless of whether everything is on track, because they flag emerging issues before they become urgent.

Proactive Risk Escalation

A CDMO project manager who only tells you about problems when they have already happened is not managing risk, they are reporting it. Proactive risk management means identifying the issues that could arise two to four weeks ahead and communicating them to the client in time for mitigation decisions to be made.

Common Failure Modes in CDMO Communication

Failure Mode	Consequence	Prevention
Multiple CDMO contacts with no clear owner	Conflicting information, unclear accountability	Assign a single project manager before work starts
Infrequent or reactive reporting	Delays surface late, options for recovery are limited	Agree reporting frequency and template at kick-off
Scope changes handled informally	Undocumented changes create disputes	Formal change control with written approvals
Technical decisions made without client visibility	Downstream surprises in GMP or dossier	Decision log shared with client in real time
No escalation path defined	Issues stall because no one has authority to resolve them	Agree named escalation contacts at both organisations

How Ardena’s Project Management Model Works

Every Ardena programme is assigned a dedicated project manager from kick-off through to delivery. That person is responsible for coordinating work across Ardena’s scientific teams, maintaining the programme timeline, and communicating progress to the client on an agreed schedule.

Ardena operates a formal change control system that ensures any modification to scope, timeline, or specification is documented and agreed before implementation. Programme status meetings are structured around a consistent agenda, and risk items are flagged in writing rather than raised informally in calls.For complex multi-site programmes, the project manager acts as the interface between Ardena’s facilities, ensuring that work in Ghent, Oss, Assen, and Pamplona is coordinated and progresses in alignment with the overall programme plan.

Why CDMO Selection Deserves More Due Diligence Than It Usually Gets

Choosing a contract development and manufacturing partner for a Phase I programme is one of the most consequential decisions an early-stage drug developer makes. It shapes your timelines, your CMC package, and your ability to respond when something unexpected happens. Yet many biotech companies spend more time evaluating clinical CROs than they spend evaluating their CDMO.

This checklist covers the questions that experienced drug developers ask when evaluating a CDMO for first-in-human manufacturing. It is not exhaustive, but it addresses the areas where gaps most often lead to problems.

Phase I CDMO Evaluation Checklist

Evaluation Area	Key Questions to Ask
GMP compliance	When was the last regulatory inspection? What were the findings? Is the facility authorised for clinical manufacturing?
Quality management system	What is the process for out-of-specification results? How are deviations investigated and closed?
Technical capability	Does the CDMO have experience with your dosage form and route of administration? What formulation technologies are available in-house?
Analytical services	Can the CDMO develop and validate your release methods in-house? How are stability studies managed?
CMC regulatory support	Does the CDMO have experience writing IND/IMPD CMC sections? Can it provide regulatory advice as well as manufacturing?
Project management	Who is your primary contact? How is communication structured? What does the escalation path look like?
Capacity and lead times	What is the current production schedule? What is the realistic timeline from project kick-off to GMP batch?
Supply chain visibility	Where do excipients and starting materials come from? What is the contingency for supplier issues?
Track record	How many Phase I batches has the facility produced in the last two years? Can it provide client references?
Flexibility for change	How does the CDMO handle formulation changes mid-programme? What is the process for scope adjustments?

The Questions Most People Forget to Ask

What Happens When the Project Manager Leaves?

In a small CDMO, the quality of your experience often depends on one or two key people. It is worth asking directly what the continuity plan is if your primary contact leaves the organisation during your programme. An organisation with robust knowledge management systems will have a clear answer.

How Does the CDMO Handle Competing Priorities?

CDMOs work with multiple clients simultaneously. When your programme and a higher-priority client need the same piece of equipment or the same specialist at the same time, something has to give. Ask how the CDMO manages competing priorities and what commitments it makes regarding dedicated capacity.

What Does ‘We Can Do That’ Actually Mean?

Some CDMOs have broad service lists but narrow actual capabilities. If a service is listed but has only been performed once or twice, the learning curve comes at your expense. Ask for the number of programmes completed using the specific technology relevant to your molecule.

How Ardena Approaches Phase I Partnerships

Ardena’s Phase I manufacturing capabilities span oral solids, complex injectables, and nanomedicines across its European network. Each programme is managed by a dedicated project manager and supported by a scientific team that has been involved from early development. The CMC regulatory function is integrated, so the team producing your GMP batches is aligned with the team writing your IND or IMPD CMC section.